Sagimet Biosciences (STU:0O2) EPS without NRI: €-1.15 (TTM As of Mar. 2026)


STU:0O2 Sagimet Biosciences Inc STU:0O2
10 GF Score
Price €6.14
! 2 Warning Signs
View Full Analysis

What is Sagimet Biosciences EPS without NRI?

Sagimet Biosciences STU:0O2 +1.66% 10 EPS without NRI is €-1.15 as of Mar. 2026. GuruFocus rates STU:0O2 with a GF Score™ of 10/100. The stock has 2 warning signs investors should review. Among 1,172 Biotechnology companies, Sagimet Biosciences ranks worse than 75.94% on this metric.

Sagimet Biosciences's earnings per share without non-recurring items for the three months ended in Mar. 2026 was €-0.29. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was €-1.15.

During the past 3 years, the average earnings per share (NRI) Growth Rate was -4.70% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was -22.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Sagimet Biosciences's EPS without NRI or its related term are showing as below:

STU:0O2' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -73.1   Med: -19.9   Max: -4.7
Current: -4.7

During the past 7 years, Sagimet Biosciences's highest 3-Year average Earnings Per Share (NRI) Growth Rate was -4.70% per year. The lowest was -73.10% per year. And the median was -19.90% per year.

STU:0O2's 3-Year EPS without NRI Growth Rate is ranked worse than
75.94% of 1172 companies
in the Biotechnology industry
Industry Median: 16.8 vs STU:0O2: -4.70

Sagimet Biosciences's EPS (Diluted) for the three months ended in Mar. 2026 was €-0.29. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €-1.15.

Sagimet Biosciences's EPS (Basic) for the three months ended in Mar. 2026 was €-0.29. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was €-1.15.


Sagimet Biosciences  (STU:0O2) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Sagimet Biosciences EPS without NRI Related Terms


Sagimet Biosciences EPS without NRI Historical Data

* Premium members only.

The historical data trend for Sagimet Biosciences's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sagimet Biosciences EPS without NRI Chart

Sagimet Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS without NRI
Get a 7-Day Free Trial -0.95 -1.30 -2.44 -1.39 -1.35

Sagimet Biosciences Quarterly Data
Dec20 Mar21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.52 -0.28 -0.34 -0.25 -0.29

STU:0O2 vs EDIT, AUTL, FBRX: EPS without NRI Comparison

For the Biotechnology subindustry, Sagimet Biosciences's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sagimet Biosciences PE Ratio without NRI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sagimet Biosciences's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Sagimet Biosciences's PE Ratio without NRI falls into.


STU:0O2
10GF Score
Sagimet Biosciences Inc STU:0O2
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sagimet Biosciences EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of €-1.15 mean?
Sagimet Biosciences (STU:0O2) has a EPS without NRI of €-1.15 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Sagimet Biosciences and its competitors. According to the industry distribution chart, Sagimet Biosciences ranks #890 out of 1172 companies in the Biotechnology industry, placing it in the top 75.9%.
Is Sagimet Biosciences' EPS without NRI too high?
Sagimet Biosciences' current EPS without NRI is €-1.15. Based on the distribution chart, Sagimet Biosciences ranks #890 out of 1172 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Sagimet Biosciences has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Sagimet Biosciences' EPS without NRI compare to EDIT and AUTL?
According to the Biotechnology industry distribution chart, Sagimet Biosciences ranks #890 out of 1172 companies for EPS without NRI. This places Sagimet Biosciences in the lower half of its industry. The industry median EPS without NRI is 16.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.80, based on 1,172 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Sagimet Biosciences and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sagimet Biosciences's current EPS without NRI is €-1.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sagimet Biosciences stock overvalued right now?
Sagimet Biosciences (STU:0O2) has a current EPS without NRI of €-1.15. The current EPS without NRI is €-1.15. Sagimet Biosciences' overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Sagimet Biosciences (STU:0O2), the current EPS without NRI is €-1.15 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sagimet Biosciences Business Description

Other Exchanges SGMT:USA
Address 155 Bovet Road, Suite 303, San Mateo, CA, USA, 94402
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
10GF Score

Get the complete analysis for STU:0O2

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.14
Price